Decreased serum vitamin D levels in Japanese patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 279, Issue C, 2015, Pages 40-45

  Niino, Masaaki ^a   Sato, Shinya ^b   Fukazawa, Toshiyuki ^c   Masaki, Katsuhisa ^b   Miyazaki, Yusei ^a   Matsuse, Dai ^b   Yamasaki, Ryo ^b   Takahashi, Eri ^a   Kikuchi, Seiji ^a   Kira, Jun ichi ^b  

^a HOKKAIDO MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Sapporo Neurology Clinic   (Japan)

Author keywords

Multiple sclerosis; Progression; Severity; Vitamin D; Vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; RECOMBINANT BETA INTERFERON; VITAMIN D BINDING PROTEIN; 1,25-DIHYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SEASONAL VARIATION; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; DISABILITY; ECOLOGY; JAPAN; MENTAL HEALTH; MIDDLE AGED; RADIOIMMUNOASSAY; SEASON; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; DISABILITY EVALUATION; ECOLOGY; FEMALE; HUMANS; JAPAN; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MULTIPLE SCLEROSIS; RADIOIMMUNOASSAY; SEASONS; VITAMIN D; VITAMIN D-BINDING PROTEIN; YOUNG ADULT;

EID: 84927172512     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.01.007     Document Type: Article

References (33)

1. Amezcua L., Chung R.H., Conti D.V., Langer-Gould A.M. Vitamin D levels in Hispanics with multiple sclerosis. J. Neurol. 2012, 259:2565-2570.
2. Armas L.A., Dowell S., Akhter M., Duthuluru S., Huerter C., Hollis B.W., Lund R., Heaney R.P. Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB dose and skin color. J. Am. Acad. Dermatol. 2007, 57:588-593.
3. Becklund B.R., Severson K.S., Vang S.V., DeLuca H.F. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6418-6423.
4. Breuer J., Schwab N., Schneider-Hohendorf T., Marziniak M., Mohan H., Bhatia U., Gross C.C., Clausen B.E., Weishaupt C., Luger T.A., Meuth S.G., Loser K., Wiendl H. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Ann. Neurol. 2014, 75:739-758.
5. Chun R.F. New perspectives on the vitamin D binding protein. Cell Biochem. Funct. 2012, 30:445-456.
6. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 2008, 324:23-33.
7. Gelfand J.M., Cree B.A., McElroy J., Oksenberg J., Green R., Mowry E.M., Miller J.W., Hauser S.L., Green A.J. Vitamin D in African Americans with multiple sclerosis. Neurology 2011, 76:1824-1830.
8. Jones G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 2008, 88:582S-586S.
9. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003, 2:117-127.
10. Kragt J., van Amerongen B., Killestein J., Dijkstra C., Uitdehaag B., Polman Ch., Lips P. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 2009, 15:9-15.
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
12. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
13. Lucas R.M., Ponsonby A.L., Dear K., Valery P.C., Pender M.P., Taylor B.V., Kilpatrick T.J., Dwyer T., Coulthard A., Chapman C., van der Mei I., Williams D., McMichael A.J. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76:540-548.
14. Miyauchi M., Hirai C., Nakajima H. The solar exposure time required for vitamin D3 synthesis in the human body estimated by numerical simulation and observation in Japan. J. Nutr. Sci. Vitaminol. 2013, 59:257-263.
15. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
16. Niino M. Vitamin D and its immunoregulatory role in multiple sclerosis. Drugs Today (Barc.) 2010, 46:279-290.
17. Niino M., Fukazawa T., Miyazaki Y., Minami N., Tashiro J., Amino I., Nonaka T., Fujiki N., Doi S., Kikuchi S. Association of serum vitamin D levels in Japanese patients with multiple sclerosis. Clin. Exp. Neuroimmunol. 2013, 4:193-200.
18. Niino M., Miyazaki Y., Fukazawa T., Kikuchi S. Vitamin D and multiple sclerosis in Asians and Caucasians: environmental and genetic aspects. Clin. Exp. Neuroimmunol. 2013, 4(Suppl. 1):59-67.
19. Pandit L., Ramagopalan S.V., Malli C., D'Cunha A., Kunder R., Shetty R. Association of vitamin D and multiple sclerosis in India. Mult. Scler. 2013, 19:1592-1596.
20. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
21. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Edan G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Sørensen P.S., Celius E.G., Lara N.T., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sá M., Salemi G., Savettieri G., Hillert J., Compston D.A. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
22. Salzer J., Hallmans G., Nyström M., Stenlund H., Wadell G., Sundström P. Vitamin D as a protective factor in multiple sclerosis. Neurology 2012, 79:2140-2145.
23. Shaygannejad V., Golabchi K., Haghighi S., Dehghan H., Moshayedi A. A comparative study of 25 (OH) vitamin D serum levels in patients with multiple sclerosis and control group in Isfahan, Iran. Int. J. Prev. Med. 2010, 1:195-201.
24. Shinpo K., Kikuchi S., Sasaki H., Moriwaka F., Tashiro K. Effect of 1,25-dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by l-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J. Neurosci. Res. 2000, 62:374-382.
25. Simpson S., Blizzard L., Otahal P., van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 2011, 82:1132-1141.
26. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 2008, 14:1220-1224.
27. Smolders J., Moen S.M., Damoiseaux J., Huitinga I., Holmøy T. Vitamin D in the healthy and inflamed central nervous system: access and function. J. Neurol. Sci. 2011, 311:37-43.
28. Soilu-Hänninen M., Airas L., Mononen I., Heikkilä A., Viljanen M., Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 2005, 11:266-271.
29. Stewart N., Simpson S., van der Mei I., Ponsonby A.L., Blizzard L., Dwyer T., Pittas F., Eyles D., Ko P., Taylor B.V. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012, 79:254-260.
30. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Taylor B.V., Kilpatrick T., Butzkueven H., McMichael A.J. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 2007, 254:581-590.
31. White P., Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol. Metab. 2000, 11:320-327.
32. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
33. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.